Avalo Therapeutics Inc. (AVTX)
NASDAQ: AVTX
· Real-Time Price · USD
9.05
0.10 (1.12%)
At close: Aug 15, 2025, 3:59 PM
9.24
2.10%
After-hours: Aug 15, 2025, 07:50 PM EDT
Avalo Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -20.77M | -13.15M | -35.34M | 23.04M | 98.46M | -121.29M | -8.17M | -5.23M | -8.19M | -9.96M | -9.81M | 3.19M | -12.99M | -22.05M | -19.2M | -17.39M | -17.11M | -30.68M |
Depreciation & Amortization | 134K | 135K | 68K | 34K | 33K | 34K | 43K | 41K | 41K | 33K | 35K | 34K | 30K | 67K | 295K | 455K | 456K | 451K |
Stock-Based Compensation | 2.72M | 3.24M | 2.9M | 1.85M | 471K | 629K | 776K | 953K | 893K | 855K | 843K | 731K | 668K | 5.31M | 1.89M | 1.76M | 3.07M | 1.45M |
Other Working Capital | n/a | n/a | 529K | 1.43M | -1.07M | -1.83M | -975K | -3.73M | 688K | -5.27M | 2.68M | 1.58M | -325K | -278K | -576K | -5.46M | 4.95M | 2.06M |
Other Non-Cash Items | 6.51M | n/a | 17.82M | -39.02M | -113.13M | 115.81M | 4.51M | 1.03M | 389K | 530K | 349K | 354K | 336K | 350K | 349K | 341K | 104K | -6.3M |
Deferred Income Tax | 16K | 8K | 114K | -14K | 7K | 7K | -9K | 8K | 7K | 8K | 8K | 5K | 6K | 9K | -18K | 9K | 10K | 21K |
Change in Working Capital | n/a | 799K | -612K | 2.59M | -1.33M | -1.26M | 85K | -3.64M | -4.16M | -1.52M | 4.64M | 1.41M | -1.52M | 246K | -421K | -1.46M | -5.73M | 10.44M |
Operating Cash Flow | -11.39M | -9.46M | -15.04M | -11.53M | -16.28M | -6.2M | -2.77M | -6.84M | -11.03M | -10.05M | -3.94M | 5.73M | -12.47M | -16.07M | -17.1M | -16.29M | -19.19M | -18.32M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a | -158K | n/a | 158K | -158K | -56K | -39K | -56K | n/a | -11K | -81K | n/a | -21K |
Cash Acquisitions | n/a | n/a | n/a | -356K | n/a | 356K | -25K | n/a | n/a | 25K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -70.86M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | -146K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | 146K | n/a | n/a | n/a | n/a | 356K | 158K | n/a | -158K | -158K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | -70.86M | n/a | n/a | n/a | n/a | 356K | -158K | n/a | 158K | -133K | -56K | -39K | -56K | n/a | -11K | -81K | n/a | -21K |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -15.24M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 13.29M | n/a | n/a |
Common Stock Repurchased | 40K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 366K | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -509K | n/a | 67.71M | -12.27M | -472K | -7.01M | n/a | n/a | -5.93M | n/a | 48K | n/a | -14.81M | n/a | 76K | n/a | 21.22M | 172K |
Financial Cash Flow | -469K | n/a | 67.71M | n/a | -472K | 108.61M | 1K | 10.7M | 598K | 13.75M | 82K | n/a | -14.78M | n/a | 76K | 47.64M | 21.22M | 37.83M |
Net Cash Flow | -82.72M | -9.46M | 52.67M | -11.53M | -16.75M | 102.77M | -2.77M | 3.86M | -10.43M | 3.56M | -3.86M | 5.69M | -27.31M | -16.07M | -17.03M | 31.27M | 2.03M | 19.49M |
Free Cash Flow | -11.39M | -9.46M | -15.04M | -11.53M | -16.28M | -6.2M | -2.92M | -6.84M | -10.87M | -10.21M | -4M | 5.69M | -12.53M | -16.07M | -17.11M | -16.37M | -19.19M | -18.34M |